PriceTargets.com logo

Annexon - ANNX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.71
  • Forecasted Upside: 410.91%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$2.88 As of 06/8/2023 01:00 AM ET
▼ -0.24 (-7.69%)

This chart shows the closing price for ANNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Annexon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANNX

Analyst Price Target is $14.71
▲ +410.91% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Annexon in the last 3 months. The average price target is $14.71, with a high forecast of $30.00 and a low forecast of $3.00. The average price target represents a 410.91% upside from the last price of $2.88.

This chart shows the closing price for ANNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Annexon. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/26/2023Bank of AmericaDowngradeBuy ➝ Neutral$8.00 ➝ $3.00Low
5/25/2023BTIG ResearchLower Target$15.00 ➝ $7.00Low
5/25/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00 ➝ $9.00Low
5/15/2023Cantor FitzgeraldReiterated RatingOverweightLow
4/19/2023Needham & Company LLCReiterated RatingBuy$24.00Low
3/14/2023Cantor FitzgeraldLower TargetOverweight$22.00 ➝ $18.00Low
3/7/2023Needham & Company LLCReiterated RatingBuy$24.00Low
3/7/2023HC WainwrightReiterated RatingBuy$30.00Low
9/16/2022Jefferies Financial GroupInitiated CoverageBuy$12.00Low
9/9/2022BTIG ResearchInitiated CoverageBuy$15.00Low
8/16/2022Cantor FitzgeraldLower TargetOverweight$27.00 ➝ $22.00Low
5/10/2022HC WainwrightLower Target$40.00 ➝ $30.00High
4/8/2022Needham & Company LLCLower TargetBuy$37.00 ➝ $24.00Medium
11/30/2021HC WainwrightInitiated CoverageBuy$40.00High
11/2/2021CowenReiterated RatingOutperformHigh
11/2/2021JPMorgan Chase & Co.Reiterated RatingOverweight$39.00High
9/28/2021Needham & Company LLCReiterated RatingBuy$37.00High
9/23/2021Cantor FitzgeraldInitiated CoverageOverweight$40.00Low
1/26/2021Needham & Company LLCInitiated CoverageBuy$37.00Medium
9/1/2020Robert W. BairdInitiated CoverageOutperformHigh
8/18/2020JPMorgan Chase & Co.Initiated CoverageOverweight$33.00Low
8/18/2020Bank of AmericaInitiated CoverageBuy$33.00 ➝ $33.00High
8/18/2020CowenInitiated CoverageOutperformHigh
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2023
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 3 very positive mentions
  • 21 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 3 very positive mentions
  • 21 positive mentions
  • 7 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Annexon logo
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $2.88
Low: $2.88
High: $3.24

50 Day Range

MA: $4.66
Low: $2.10
High: $6.37

52 Week Range

Now: $2.88
Low: $2.07
High: $7.65

Volume

2,106,846 shs

Average Volume

698,155 shs

Market Capitalization

$152.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Annexon?

The following equities research analysts have issued reports on Annexon in the last year: Bank of America Co., BTIG Research, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Needham & Company LLC.
View the latest analyst ratings for ANNX.

What is the current price target for Annexon?

7 Wall Street analysts have set twelve-month price targets for Annexon in the last year. Their average twelve-month price target is $14.71, suggesting a possible upside of 410.9%. HC Wainwright has the highest price target set, predicting ANNX will reach $30.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $3.00 for Annexon in the next year.
View the latest price targets for ANNX.

What is the current consensus analyst rating for Annexon?

Annexon currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANNX will outperform the market and that investors should add to their positions of Annexon.
View the latest ratings for ANNX.

What other companies compete with Annexon?

Other companies that are similar to Annexon include XBiotech, Oramed Pharmaceuticals, Silence Therapeutics, ProQR Therapeutics and Larimar Therapeutics. Learn More about companies similar to Annexon.

How do I contact Annexon's investor relations team?

The company's listed phone number is 650-822-5500 and its investor relations email address is [email protected]. The official website for Annexon is www.annexonbio.com. Learn More about contacing Annexon investor relations.